laboratori corp america hold lh nyse qqq
labcorp face challeng diagnost shine drug
updat forecast estim jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim jul
price data sep
rate updat sep
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
particip highli attract duopoli offer bright
prospect healthcar move toward reform payment model
even though hospit still domin billion diagnost
market labcorp carv signific slice pie
serial acquisit addit covanc drug-develop
expertis offer labcorp avenu monet larg patient
importantli labcorp single-mindedli pursu greater
effici translat abil reduc cost
quickli reimburs cut come pike firm
invest greater autom system decreas
number employe involv sort run test
labcorp also put signific resourc behind beef
inform technolog capabl result physician
easili access test inform time manner
patient schedul blood draw increas conveni
admir manag team consist focus
strategi long term expect labcorp
invest today reap reward futur year
labcorp take advantag long-term secular trend
bode well diagnost industri prolifer
new test grow new diseas marker genet mutat
pharmacogenom
implic discov new
reimburs model inspir healthcar reform lead
doctor hospit send test lower-cost produc
pama reimburs pressur medicar remain
strongest near-term headwind howev expect could eas
hospital-bas lab reimburs higher
level includ recalcul medicar clinic lab
fee schedul question remain whether hospital-bas
lab abl compli pama collect report
requir lab industri advoc
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
nation second-largest
laboratori corpor america
independ clinic laboratori roughli independ lab
market compani oper patient-servic center
offer broad rang clinic lab test rang routin blood
urin screen complex oncolog genom test addit
covanc labcorp also sizabl footprint global contract
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
labcorp face challeng diagnost shine
labcorp face mix move part made second-
quarter result challeng dissect whole
firm remain track full-year expect
stand behind fair valu estim continu
hold temper expect diagnost segment
labcorp once-exclus contract key privat
payer open includ rival quest protect
access medicare-l reimburs pressur bear
year despit near-term hindranc
remain confid labcorp narrow moat remain
intact think largest lowest-cost lab best
posit weather current reimburs squeez
longer haul like ultim make
though quarterli volum display soft revenue-
year year driven primarili soft
genet test loss exclus larg managed-
care firm view near-term stress volum
expect labcorp particip
unitedhealth
prefer lab network result volum growth
initi period share volum quest unitedhealth
plan make easier physician refer patient
labcorp quest
also mean put
administr obstacl use higher-cost out-of-
network lab help funnel volum larg
last sever quarter weve seen covanc drug
develop segment perform strongli firm
data mine tool improv last year given
labcorp signific leg smaller contract research
organ identifi locat potenti clinic
trial patient base data oper strength
anticip covanc segment deliv least
market growth near-optim current market
final like labcorp new program reach
directli patient clinic trial enrol thu far
firm primarili reli indirect path patient
contact patient physician howev sinc
covanc acquisit close labcorp ask
patient whether theyd like inform clinic trial
take place nearbi strategi make lot sens
us wed assum would take year collect enough
patient opt make databas use way
underestim labcorp firm roll new
patient-direct featur covanc client base
diagnost code test result geograph locat
labcorp directli target patient like qualifi
nudg sponsor websit enrol
novel util labcorp patient base think
competit would difficult time replic
sinc dont regular contact patient
diagnost lab
stand behind fair valu estim per
share continu expect robust growth drug
develop busi sustain five
consecut quarter growth addit chiltern
give labcorp greater footprint small medium
size biopharma area assum new medicar clinic
lab fee schedul adjust first three-year cycl
rate set greater impact
taper reimburs data
collect incorpor next cycl medicar
growth averag annual follow five
year near term anticip volum growth
solidifi thank increas healthcar util
gradual transit bundl capit reimburs
partial off-set medicar cut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
underli diagnost busi would rate firm
uncertainti medium
bull case valu share scenario
assum robust volum gain better-than-expect
cost contain effici respons
pama-l reimburs pressur also
assum faster growth covanc clinic trial
busi result adjust annual top-lin growth
higher throughput assum
leverag
translat gain adjust oper
bearish scenario project sluggish volum growth
number uninsur patient rise trump
administr effort erod coverag drug
develop segment fail reach histor growth level
also bake increas bad debt expens
estim oper margin fall basi
point next five year due weak volum
tight price pressur case put fair valu estim
per share
labcorp narrow moat base vast nation
infrastructur translat consider scale
advantag smaller region lab independ
diagnost test industri primari test lab
patient-servic center across unit state
labcorp abl run test specimen day
substanti lower cost hospit
doctor offic smaller independ lab popul
market labcorp abil accommod higher
throughput extens use autom afford
firm much lower cost structur -- significantli lower
hospit smaller independ lab
advantag also mean labcorp model character
keep long-term trend anticip
increas growth genom esoter test compar
routin test labcorp done good job
launch new complex test lead us believ
annual esoter test volum outpac market growth
also think special test carri higher
price tag routin counterpart result averag
annual price increas long term
off-set reimburs pressur routin
test still make bulk labcorp test mix
think labcorp invest covanc
allianc larg payer put
firm strong posit take advantag emerg
opportun longer term demonstr
valu refer lab add beyond deliveri reliabl
accur test data anticip acquisit add
approxim per year total revenu growth
think labcorp make consider improv
adjust oper margin -- tune basi
point -- time frame
base averag volatil cash flow labcorp
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
substanti oper leverag oper leverag
work firm wake recess
healthcar util fell howev util
return growth labcorp also benefit though
addit cro busi pressur margin
although price ration recent past
potenti price competit keep us award
payer would typic rather negoti largest
refer lab includ labcorp provid best
geograph coverag insur base instead
cobbl togeth market-by-market coverag
multipl smaller region lab departur
exclus agreement use character contract
privat payer
organ begun shift differ model
allow lowest-cost produc labcorp
quest in-network lab think reflect
influenc value-bas healthcar reform becom
econom attract encourag patient use
low-cost produc place expens
hospital-bas lab instead pit labcorp quest
eke save also reduc
patient access lower-cost test
final labcorp scale reach make attract
partner research invent variou diagnost test
distribut channel sell
test labcorp recent invest dedic lab
focus companion diagnost anoth indic
firm think creativ
close partner entiti healthcar arena
think addit covanc solidifi labcorp
narrow moat -- previous award covanc narrow
moat right contract research organ
moatiest part busi late-stag clinic
trial global infrastructur critic easili
replic legaci covanc busi also benefit
intang asset includ expertis local countri
cultur regulatori agenc chang regul
research design data analyt knowledg key diseas
state close relationship pharmaceut
biotech client clinic trial busi tap
labcorp enorm patient databas order better
match elig patient appropri trial reduc
enrol time capabl give labcorp advantag
competit
see labcorp moat trend posit think labcorp
particularli well-posit take advantag
long-term opportun emerg wake
healthcar reform evolut volume-bas
value-bas reimburs payer assess valu
link chain patient diagnosi
treatment simultan widespread adopt
new digit tool manipul analyz patient data
two factor set stage diagnost
compani demonstr valu diagnost
test -- specif much time money save --
captur valu tradit gone
therapeut agent end-stag treatment new
avenu growth diagnost compani exist
healthcar reform push labcorp
quest new nonexclus contract
latest step closer collabor bring diagnost data
claim data togeth analyt use
see new growth prospect horizon
diagnost compani abil ultim capit
depend well develop capabl beyond
current core compet logist lab qualiti
must develop new expertis data collect
integr well informat point think
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
capabl anticip labcorp find new
applic covanc compet tie diagnost
measur therapi patient outcom cost
labcorp pull ahead quest prepar
first labcorp alreadi laid groundwork
integr inform technolog platform --
first step toward possibl aggreg test data
second labcorp alreadi dip toe water
come informat challeng
measur cost save diagnost particular
think firm experi demonstr result
small-scal kidney stone manag chronic
kidney diseas monitor program give labcorp leg
competit futur expect see labcorp
target key diseas area early-detect
treatment monitor program could implement
provid cost save addit covanc late-stag
trial expertis boost labcorp abil conduct
third applaud labcorp savvi move launch new
enlighten genom unit firm initi
address immens potenti next-gener
sequenc although yet reach point
routin sequenc take place patient
question technolog alreadi shape
realm oncolog see applic heart
diseas central nervou system neurolog labcorp
busi build capabl area new
geneticist staff well specialist analyt
valu amass proprietari test
patient data labcorp alreadi detect trend
enlighten health busi put firm strong
posit key owner data line
final acquisit covanc expertis data
analyt clinic trial give labcorp big boost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
dissip new
nonexclus relationship help labcorp navig
reimburs cut
could strain labcorp even
eas expect
oth complex labor-intens esoter test
reimburs higher rate often outsourc
hospit independ lab labcorp funnel
resourc broaden menu complex esoter
test help maintain healthi margin
olabcorp abl keep less profit
capit managed-car contract minimum
account diagnost revenu
olabcorp need analyt expertis covanc
would diminish labcorp retain
oit could take longer anticip bundl
payment becom norm provid
case increas volum ensu oper
leverag could five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
acquisit covanc increas labcorp debt
leverag substanti fund acquisit earli
labcorp borrow five-year term loan may
prepaid without penalti billion new senior
unsecur note matur
end decemb labcorp debt stood
billion time ebitda time prior
acquisit howev end debt/ebitda
fallen time firm debt tick time
expect firm hit debt/ebitda around
end year labcorp yet reach target
ratio time longer term comparison quest
aim low long run even slightli
oper higher cash level may keep net
leverag roughli line even slightli lower
quest long run addit million
cash held balanc sheet end
estim labcorp abl gener
billion averag annual free cash flow next five
year plenti help firm manag
debt oblig intern mean
base averag volatil cash flow labcorp
underli diagnost busi rate firm
uncertainti medium despit mani long-term clinic
undercurr favor labcorp see
potenti near-term bumpi sever great
recess spur declin patient volum across
specialti consum delay seek
healthcar especi nonacut nonsymptomat
condit seen gradual resumpt growth
patient traffic unfavor macro condit aris
labcorp volum could drop key measur
afford act dismantl could lead
less volum higher bad debt expens chang
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
reimburs penetr high-deduct plan
substanti cost-shar measur also left
patient larger out-of-pocket burden could
becom perenni drag growth diagnost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
ceo/chairman board/
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
assign standard stewardship rate labcorp david
king took role ceo earli follow
retir thoma mahon held posit
nearli decad brief transit period king also
took titl chairman think king prior
experi labcorp good foundat
core diagnost busi impress
king navig compani
increasingli competit industri landscap steep
volum well
unorthodox integr covanc clinic trial
busi king previou experi labcorp
corpor plan strateg develop function
also advantag perspect especi
consid firm on-going relianc acquisit
smaller lab opportun arisen
adjac area howev note labcorp
compens polici rel gener king
earn million million
past three year
one hand appreci king vision
understand healthcar system lurch
lab need adapt potenti move new line
busi think acquisit covanc reflect
king view simpli gener data longer enough
captur valu healthcar futur healthcar
competitor also compet basi proprietari
ownership data well abil translat
data usabl medic knowledg hand
think king tendenc appli great pressur
execut team could lead greater turnov may
prevent firm realiz potenti emerg
overal appreci manag execut
year firm maintain great major
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
contract payer provid custom even
rack new client sizabl empir
cross shield plan new york importantli
like labcorp capital-alloc decis particular
firm exercis financi disciplin acquisit
strategi acquisit accret shortli
close firm avoid write goodwil
unlik rival quest labcorp embrac model
includ manag ownership hospital-bas lab
asset think difficult extract much valu
independ lab hospit outreach program
although labcorp pay dividend manag
funnel return sharehold form share
buyback applaud firm acceler repurchas
share trade discount
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
diagnost lab industri aim improv medicar
reimburs addit hospit lab jul
diagnost industri begun see full
more-dramatic-than-expect effect reduct
medicar clinic lab fee schedul roll
industri fight back strenuous
recent industri prompt introduct
bipartisan bill laboratori access beneficiari act
hous doesnt shift fair valu
estim narrow-moat labcorp
ratchet pressur higher-cost hospital-
base lab compli reimburs report
requir contain protect access
medicar act fair valu narrow-moat sonic
healthcar also unchang
pama laid conceptu framework shift
medicar diagnost test reimburs market
price base rate privat payer paid test
congress left center medicar medicaid
servic figur best way implement
program collect price data diagnost lab
unfortun first round rate-set
requir hospital-bas lab compli
collect submiss data lab
compli result new medicar test price
heavili skew toward labcorp quest largest
fortun current round data collect
requir roughli hospital-bas lab meet
report requir think help improv
medicar reimburs outlook
lab
lab act primarili aim delay collect
report period suppos happen
year order hospital-bas lab upgrad
test volum
handl
reimburs data granular level current
hospital-bas lab equip report diagnost test
volum payer price plan
consid sever first round cut
expect weve begun see smaller independ lab
close door put sale
gener bode well longer term labcorp
quest built busi serial
acquisit smaller lab howev dynam rais
issu patient access seek creat
balanc cost effici
illinoi
exampl spring labcorp acquir privat held
metropolitan medic laboratori serv
citi metro area davenport bettendorf iowa
separ mississippi river molin
total popul
approxim peopl labcorp intend integr
busi large-scal lab oper
continu metropolitan medic mobil lab
servic nurs home long-term care facil
home-bound senior patient risk lose access
diagnost test concern
higher-cost hospital-bas lab help
preserv access patient
diagnost lab industri aim improv medicar
reimburs addit hospit lab jul
diagnost industri begun see full
more-dramatic-than-expect impact reduct
medicar clinic lab fee schedul roll
industri fight back strenuous
recent industri prompt introduct
bipartisan bill laboratori access beneficiari act
hous doesnt shift fair valu
estim narrow-moat labcorp
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
ratchet pressur higher-cost hospital-
base lab compli reimburs report
requir contain protect access
pama laid conceptu framework shift
medicar diagnost test reimburs market
price base rate privat payer reimburs
test congress left center
medicar medicaid servic figur best way
implement program collect price data
diagnost lab unfortun first round rate-
set requir hospital-bas
lab compli data collect submiss
lab compli result new medicar
test price heavili skew toward labcorp quest
structur fortun current round data
collect requir roughli hospital-
base lab meet report requir think
help improv medicar reimburs pictur
lab
lab act primarili seek delay collect
report period suppos happen right
year order hospital-bas lab
upgrad system handl test volum
reimburs data granular level current
hospital-bas lab equip report diagnost test
volum payer price plan
consid sever first round cut
expect weve begun see smaller independ lab
close door put sale
gener bode well longer term labcorp quest
built serial acquisit
smaller lab howev dynam rais issu patient
access seek balanc cost effici
illinoi
exampl spring labcorp acquir privat held
metropolitan medic laboratori serv
citi metro area davenport bettendorf iowa
separ mississippi river molin
total popul
approxim peopl labcorp intend integr
busi large-scal lab oper
continu metropolitan medic mobil lab
servic serv nurs home long-term care facil
home-bound senior patient risk lose access
diagnost test becom concern
weight median privat payer reimburs includ
higher-cost hospital-bas lab help
preserv access patient
medicar cut press labcorp first quarter
chang fair valu estim apr
labcorp post solid first-quart perform held
surpris medicar reimburs pressur
continu bear refer lab industri
leav fair valu estim unchang quarter
includ number offset factor diagnost
divis includ divestitur foreign exchang
headwind pleas see organ
 pipelin indic
robust group lab recept consolid
howev reorgan largest lab handl
nurs home market suspect medicar along
entir lab industri must wrestl
readjust pama cut arent widespread cut
access patient remain confid labcorp
narrow econom moat stem compel cost
structur put firm strong posit weather
near-term cut flow
although labcorp quarterli organ test volum growth
overshadow rival quest increas
pleas see labcorp revenu per requisit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
reimburs cut cap per year
first round reset clinic lab fee schedul
second round rate reset
maximum cut cap per year consid
signific effect medicar cut lab
last year prospect substanti reduc patient
access specul keen avoid full
impact increment cut would
like hurt access
declin consider better
decreas quest saw also
pleasantli surpris see loss exclus
labcorp contract horizon
cross shield didnt seem take much bite
labcorp diagnost busi suggest payer
employ patient via high-deduct
plan align interest choos low-cost
produc labcorp expens
hospital-bas smaller
underscor confid labcorp moat
prospect succeed value-bas environ
second three-year cycl roll updat
medicar clinic lab fee schedul set begin
offer potenti reimburs pressur eas
think new definit applic lab
encompass higher-cost hospital-bas lab
highli favor develop labcorp quest
howev likelihood hospital-bas lab
compli report requir remain open
question mind medicar clinic lab fee
schedul increas critic mass hospit
need collect report price privat payer
point skeptic mani hospital-
base lab equip appropri inform
technolog tool abl track test volum
payment payer plan collect data
start jan wrap june
lab end year submit
data
labcorp quest manag indic
entir lab test industri work delay
collect report time frame order buy
higher-cost lab time compli think would
interest lengthen report period maxim
hospital-bas lab particip pama written
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
laboratori corp america hold lh nyse qqq
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
